Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.

NCT02271217 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT02271217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02271217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
October 31, 2016
Enrollment
377 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

post-ischemic stroke